Liang Xisong, Wang Zeyu, Dai Ziyu, Zhang Hao, Cheng Quan, Liu Zhixiong
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
J Oncol. 2021 Jul 31;2021:7840007. doi: 10.1155/2021/7840007. eCollection 2021.
Malignant neoplasms are characterized by poor therapeutic efficacy, high recurrence rate, and extensive metastasis, leading to short survival. Previous methods for grouping prognostic risks are based on anatomic, clinical, and pathological features that exhibit lower distinguishing capability compared with genetic signatures. The update of sequencing techniques and machine learning promotes the genetic panels-based prognostic model development, especially the RNA-panel models. Gliomas harbor the most malignant features and the poorest survival among all tumors. Currently, numerous glioma prognostic models have been reported. We systematically reviewed all 138 machine-learning-based genetic models and proposed novel criteria in assessing their quality. Besides, the biological and clinical significance of some highly overlapped glioma markers in these models were discussed. This study screened out markers with strong prognostic potential and 27 models presenting high quality. Conclusively, we comprehensively reviewed 138 prognostic models combined with glioma genetic panels and presented novel criteria for the development and assessment of clinically important prognostic models. This will guide the genetic models in cancers from laboratory-based research studies to clinical applications and improve glioma patient prognostic management.
恶性肿瘤的特点是治疗效果差、复发率高和广泛转移,导致生存期短。以往的预后风险分组方法基于解剖、临床和病理特征,与基因特征相比,其区分能力较低。测序技术和机器学习的更新推动了基于基因面板的预后模型的发展,尤其是RNA面板模型。胶质瘤在所有肿瘤中具有最恶性的特征和最差的生存率。目前,已有许多胶质瘤预后模型被报道。我们系统地回顾了所有138个基于机器学习的基因模型,并提出了评估其质量的新标准。此外,还讨论了这些模型中一些高度重叠的胶质瘤标志物的生物学和临床意义。本研究筛选出具有强预后潜力的标志物和27个高质量模型。总之,我们全面回顾了138个结合胶质瘤基因面板的预后模型,并提出了开发和评估临床重要预后模型的新标准。这将指导癌症基因模型从基于实验室的研究向临床应用转化,并改善胶质瘤患者的预后管理。